Thyme Care garners $97M, achieves profitability
Published by
MobiHealth News
on
Thyme Care was recently featured in MobiHealthNews after securing $97M in Series D funding and achieving profitability within a year of growth. The article reports that the round brought the total capital raised to $275M, with participation from both existing investors (CVS Health Ventures, a16z Bio + Health, Concord, Foresite, Town Hall, Frist Cressey, AlleyCorp) and strategic newcomers (Morgan Health, Humana, Memorial Hermann, Texas Oncology). Preview below:
Thyme Care, which offers a value-based cancer care platform, has secured $97 million in Series D funding and announced it has achieved profitability in a year of growth, which includes new Medicare, employer and commercial contracts.
Existing investors CVS Health Ventures, a16z Bio +Health, Concord Health Partners, Foresite Capital, Town Hall Ventures, Frist Cressey Ventures and AlleyCorp participated in the round.
New strategic investors JPMorganChase's Morgan Health, Humana, Memorial Hermann Health System and Texas Oncology also contributed.
The round brings the company's total raise to $275 million.
WHAT IT DOES
The Nashville-based company, founded in 2020, offers an oncology-focused platform that delivers 24/7 virtual care navigation.
The company's offering, Thyme Box, is a care management platform that provides care navigation and oncology analytics.
Thyme Care Connect allows individuals to connect with support, track their symptoms and access educational content.
Thyme Care Signal enables oncology analytics and guidance sharing between Thyme Care and the company's oncology partner. Through the platform, information is shared with one's provider team, which includes updates and recommendations and allows for direct communication.